Loading patent…
AssigneeOncogen
InventorsJoseph P. Brown, Charles D. Estin, Gregory D. Plowman, Timothy M. Rose, Karl E. Hellstrom, Ingegerd Hellstrom, Anthony F. Purchio, Shiu-Lok Hu, Sridhar Pennathur
Estimating the term…
Peptides or proteins related to a melanoma associated antigen are described. These are produced in large quantities via recombinant DNA techniques and/or by chemical synthetic methods. The peptides or proteins can be used as immunogens in vaccine formulations which can induce an immune response that selectively destroys melanoma cells in a vaccinated individual. Where the peptides or proteins are expressed by a recombinant virus, inactivated or live virus vaccine formulations may be prepared.
A recombinant virus, the genome of which comprises a nucleotide sequence encoding a melanoma-associated p97 antigen or an antigenic portion thereof, which is under the control of a second nucleotide sequence that regulates gene expression so that a melanoma associated p97 antigen, or an antigenic portion thereof, is expressed in a host infected with the virus.
A recombinant virus the genome of which comprises a nucleotide sequence encoding a melanoma-associated p97 antigen, or an antigenic portion thereof, which comprises the nucleotide sequence substantially as depicted in FIG. 3 or any portion thereof encoding an antigenic peptide or protein, and which is under the control of a second nucleotide sequence that regulates gene expression so that a melanoma-associated p97 antigen, or an antigenic portion thereof, is expressed in a host infected with the virus.
A recombinant DNA vector comprising p97b.
A recombinant DNA vector comprising pMTp97b.
A recombinant DNA vector comprising pSVp97a.
Dependencies are inferred from the claim text.